In the new study, published this 28 June in Nature, scientists examined the genome of 67,852 individuals and applied three statistical methods to zoom in on which genetic variants were actively implicated in the disease. Of the regions of the genome associated with IBD that were studied, 18 could be pin-pointed to a single genetic variant with more than 95 per cent certainty. The results form a basis for more effective prescription of current treatments for the disease as well as the discovery of new drug targets.
More than 850,000 people suffer from IBD in Europe. IBD is a debilitating disease in which the body’s own immune system attacks parts of the digestive tract. The exact causes of this disease are unclear, and there currently is no cure.
To understand more about the genetics underlying IBD, researchers have conducted genome wide association studies and previously found hundreds of genetic variants linked to the disease. However, it was not certain which specific genes were actually implicated by those variants.
Dr Jeffrey Barrett, joint lead author from the Wellcome Trust Sanger Institute said: “We have taken the biggest ever data set for IBD and applied careful statistics to narrow down to the individual genetic variants involved. Now we have a clearer picture of which genes do and do not play a role in the disease. We are zooming in on the genetic culprits of IBD.”
The high resolution map of the disease enabled scientists to see which variants directly influence disease, and to separate them from other variants which happen to be located near each other in the genome.
Dr Hailiang Huang, first author from the Massachusetts General Hospital and Broad Institute said: “An issue with studying complex diseases is that it can be hard to move from genetic associations, usually including many genetic variants of similar evidence, to knowing exactly which variants are involved. We need to be careful in deciding when we are sure we have the right variant. This new technique helps us to pinpoint which genetic variants are implicated in IBD with greater confidence.”
Professor Michel Georges, joint lead author from the GIGA Institute of the University of Liège said: “These results will help towards rational drug discovery for complex human diseases like IBD, and possibly for the development of personalised medicine by finding biomarkers for more effective prescription of existing drugs.”
Hailiang Huang et al. (2017) Fine-mapping inflammatory bowel disease loci to single variant resolution. Nature. DOI: 10.1038/nature22969
This work was supported by Wellcome, the Netherlands Organisation for Scientific Research, the Canadian Institutes of Health, the Belgian Welbio and BELSPO-IUAP programmes and others. For full funding information please refer to the publication.